Evidence map›Paper›PMID 36290007›Full record

ArticleAntibiotics (Basel, Switzerland)2022

Increased Susceptibility of

Hoonhee Seo, Sukyung Kim, Hafij Al Mahmud, Omme Fatema Sultana, Youngkyoung Lee, Youjin Yoon, Md Abdur Rahim, Sujin Jo, Jiwon Choi, Saebim Lee and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Hoonhee SeoDepartment of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan-si 31151, Korea.
Sukyung KimProbiotics Microbiome Convergence Center, Soonchunhyang University, Asan-si 31538, Korea.
Hafij Al MahmudDepartment of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan-si 31151, Korea.
Omme Fatema SultanaDepartment of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan-si 31151, Korea.
Youngkyoung LeeDepartment of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan-si 31151, Korea.ORCID 0000-0001-5426-4050
Youjin YoonDepartment of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan-si 31151, Korea.
Md Abdur RahimDepartment of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan-si 31151, Korea.
Sujin JoDepartment of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan-si 31151, Korea.ORCID 0000-0002-1260-7702
Jiwon ChoiCollege of Pharmacy, Dongduk Women's University, Seoul 02748, Korea.ORCID 0000-0002-0786-6187
Saebim LeeDepartment of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan-si 31151, Korea.
Ho-Yeon SongDepartment of Microbiology and Immunology, School of Medicine, Soonchunhyang University, Cheonan-si 31151, Korea.
Soonchunhyang University · KRDongduk Women's University · KR

Funding

Korea Health Industry Development Institute HI13C0828Ministry of Trade, Industry and Energy 20018499Soonchunhyang University Soonchunhyang University Research Fund
6 · The paper itself

Abstract

Tuberculosis, an infectious disease, is one of the leading causes of death worldwide. Drug-resistant tuberculosis exacerbates its threat. Despite long-term and costly treatment with second-line drugs, treatment failure rates and mortality remain high. Therefore, new strategies for developing new drugs and improving the efficiency of existing drug treatments are urgently needed. Our research team reported that PPs, a new class of potential anti-tuberculosis drug candidates, can inhibit the growth of drug-resistant

Indexed as

drug-resistantethionamide (ETH) boosterMycobacterium tuberculosisPPsRv0560c

Identifiers

PMID36290007
PMCPMC9598822
OpenAlexW4303579121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.